An experimental Alzheimer’s drug, hailed as a breakthrough, slows cognition decline in people with early-stage disease, according to a new study in the New England Journal of Medicine. The drug, lecanemab, is a monoclonal antibody (mAb) designed to clear amyloid plaques in the brain that many think are a root cause of Alzheimer’s disease.

The study, co-authored by Paul Aisen, MD, director of the Keck School of Medicine of USC’s Alzheimer’s Therapeutic Research Institute, proves for the first time the that it’s possible to slow the progression of Alzheimer’s.

To read the full story and view an accompanying video, click here.